Agilent Technologies generated $1,878 million in quarterly revenue, up from $1,738 million in the comparable quarter, while Net Income reached $362 million. Investors can assess the results through $1.28 basic and diluted earnings per share, alongside segment Revenue of $746 million for Life Sciences and Diagnostics Markets and $786 million for Agilent CrossLab.

Key Highlights

  • Products generated $1,333 million in revenue, compared with $1,230 million in the comparable quarter.
  • Agilent CrossLab recorded $786 million in revenue, ahead of $746 million from Life Sciences and Diagnostics Markets.
  • Basic and Diluted Earnings per Share were both $1.28 for the quarter.

Agilent Technologies, Inc. (NYSE: A) produced $1,878 million in revenue for the three months ended July 31, 2026, compared with $1,738 million in the comparable quarter. Net income was $362 million, while basic and diluted earnings per share each reached $1.28. Income from operations was $444 million.

Quarterly Revenue And Earnings

Products contributed $1,333 million of quarterly revenue, compared with $1,230 million in the comparable period. Services and other revenue came to $545 million, versus $508 million previously. Total costs were $836 million, down from $850 million in the comparable quarter. Research and Development expense was $123 million, compared with $111 million, while selling, general and administrative expense was $475 million, up from $417 million. Total costs and expenses reached $1,434 million, compared with $1,378 million in the comparable period. Income before taxes was $444 million, compared with $366 million. The provision for income taxes was $82 million, versus $30 million, and net income was $362 million compared with $336 million.

Segment Sales Breakdown

Life Sciences and Diagnostics Markets generated $746 million in revenue, compared with $670 million in the comparable quarter. Agilent CrossLab revenue was $786 million, up from $744 million, while Applied Markets produced $346 million versus $324 million. The Americas contributed $761 million across the three segments. Europe generated $504 million, and Asia Pacific contributed $613 million. Pharmaceutical and Biotechnology revenue was $707 million, followed by $430 million from Chemicals and Advanced Materials. Diagnostics and Clinical generated $284 million, Environmental and Forensics contributed $171 million, Food produced $158 million and Academia and Government generated $128 million. Instrumentation revenue was $643 million. Non-instrumentation and other revenue totaled $1,235 million.

Nine-Month Financial Totals

For the nine months ended July 31, 2026, total revenue was $5,511 million, compared with $5,087 million in the comparable period. Products contributed $3,911 million and services and other revenue generated $1,600 million. Net income for the nine-month period was $1,006 million, compared with $869 million. Basic and diluted earnings per share were each $3.55, compared with $3.05. Income from operations reached $1,196 million, compared with $1,036 million. Total costs and expenses were $4,315 million, versus $4,051 million. Nine-month segment revenue included $2,157 million from Life Sciences and Diagnostics Markets, $2,303 million from Agilent CrossLab and $1,051 million from Applied Markets. Regional revenue totaled $2,203 million in the Americas, $1,540 million in Europe and $1,768 million in Asia Pacific.

Cash And Operating Activity

Cash and cash equivalents stood at $1,758 million as of July 31, 2026, compared with $1,789 million as of October 31, 2025. Net cash provided by Operating Activities for the nine months was $1,064 million, compared with $1,014 million in the comparable period. Agilent Technologies paid approximately $150 million under variable and incentive pay programs during the nine months, compared with $98 million previously. Net cash paid for income taxes was $376 million, versus $304 million. Accounts Receivable provided $16 million of cash, compared with $44 million of cash used in the comparable period. Inventory used $110 million of cash, compared with $72 million. Days’ sales outstanding was 71 days as of July 31, 2026, compared with 72 days as of July 31, 2025. Inventory days on hand were 120 days, compared with 107 days, reflecting strategic inventory purchases described as supporting tariff-related risk mitigation, Supply assurance and supply-chain management.

Peers Moving on This News